IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.077
AS - Asia 6.940
EU - Europa 5.254
SA - Sud America 1.547
AF - Africa 185
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 2
Totale 26.022
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.537
SG - Singapore 2.533
CN - Cina 1.821
RU - Federazione Russa 1.689
IT - Italia 1.556
BR - Brasile 1.232
VN - Vietnam 881
HK - Hong Kong 483
BD - Bangladesh 446
GB - Regno Unito 422
CA - Canada 334
DE - Germania 320
FR - Francia 257
FI - Finlandia 235
IN - India 156
IE - Irlanda 142
MX - Messico 132
TR - Turchia 127
NL - Olanda 110
AR - Argentina 103
PL - Polonia 88
UA - Ucraina 87
SE - Svezia 83
ID - Indonesia 75
IQ - Iraq 66
ZA - Sudafrica 66
ES - Italia 63
PK - Pakistan 58
EC - Ecuador 55
AT - Austria 45
JP - Giappone 45
IL - Israele 43
CO - Colombia 38
VE - Venezuela 33
AE - Emirati Arabi Uniti 30
LT - Lituania 27
MA - Marocco 27
UZ - Uzbekistan 27
PY - Paraguay 26
CL - Cile 21
MY - Malesia 20
PE - Perù 18
SA - Arabia Saudita 18
EG - Egitto 16
CH - Svizzera 15
CR - Costa Rica 14
KE - Kenya 14
RO - Romania 14
TN - Tunisia 14
AU - Australia 13
DZ - Algeria 13
BE - Belgio 12
PH - Filippine 12
AL - Albania 11
DO - Repubblica Dominicana 11
AZ - Azerbaigian 10
UY - Uruguay 10
CZ - Repubblica Ceca 9
DK - Danimarca 9
JM - Giamaica 9
JO - Giordania 9
NP - Nepal 9
GR - Grecia 8
GT - Guatemala 8
MC - Monaco 8
SN - Senegal 8
HN - Honduras 7
BO - Bolivia 6
CI - Costa d'Avorio 6
HU - Ungheria 6
IR - Iran 6
KZ - Kazakistan 6
MD - Moldavia 6
OM - Oman 6
PA - Panama 6
TW - Taiwan 6
TH - Thailandia 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BG - Bulgaria 4
BH - Bahrain 4
BY - Bielorussia 4
GY - Guiana 4
KR - Corea 4
PS - Palestinian Territory 4
SI - Slovenia 4
AO - Angola 3
BB - Barbados 3
LB - Libano 3
LV - Lettonia 3
NI - Nicaragua 3
NO - Norvegia 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BT - Bhutan 2
CG - Congo 2
ET - Etiopia 2
GD - Grenada 2
GE - Georgia 2
HR - Croazia 2
Totale 25.968
Salva come PNG Salva come JPEG
Città #
Dallas 2.452
Singapore 1.396
Chicago 869
Ashburn 852
San Jose 800
Los Angeles 658
Beijing 630
Hong Kong 468
Salt Lake City 393
Moscow 317
Ho Chi Minh City 295
Buffalo 276
New York 251
Milan 219
Tampa 205
Hanoi 195
Chandler 181
Elk Grove Village 169
Council Bluffs 163
Santa Clara 157
Helsinki 151
São Paulo 148
Rome 144
Dublin 141
Lauterbourg 126
The Dalles 124
Boardman 121
Wilmington 111
Hefei 107
Munich 102
Pisa 97
Beauharnois 89
Orem 88
Fairfield 84
San Mateo 82
Sterling 81
Montreal 80
Warsaw 75
Florence 74
London 74
Lancaster 73
Houston 71
Seattle 70
Istanbul 66
Mexico City 66
Cambridge 65
Denver 62
Frankfurt am Main 62
Miami 62
Toronto 60
Amsterdam 59
Poplar 59
Atlanta 56
Phoenix 55
Stockholm 54
Brooklyn 50
Dulles 48
Chennai 45
Lappeenranta 44
Ottawa 44
Da Nang 43
Tokyo 43
Johannesburg 42
Portsmouth 40
Rio de Janeiro 40
Nuremberg 39
Stevenage 38
Bologna 35
Detroit 35
Turku 35
Boston 34
Columbus 34
Tel Aviv 34
Manchester 33
Southend 33
Falls Church 32
Hangzhou 32
Kansas City 32
Belo Horizonte 31
Naples 31
Washington 31
Haiphong 30
Jacksonville 30
Lawrence 30
Woodbridge 30
Palermo 29
Ankara 28
Figino 27
Guangzhou 27
Lucca 27
Pittsburgh 26
Mumbai 25
Paris 25
Genoa 24
Porto Alegre 24
San Francisco 24
Tashkent 24
Turin 24
Guayaquil 23
Shanghai 22
Totale 15.462
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.843
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.703
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 724
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 615
A simple echocardiographic score to rule out cardiac amyloidosis 387
A simple echocardiographic score to rule out cardiac amyloidosis 354
[Central apneas and cardiovascular diseases] 335
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 324
Eligibility for vericiguat in a real‐world, contemporary heart failure population 298
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 296
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 295
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 291
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 268
Atrial amyloidosis: mechanisms and clinical manifestations 261
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 260
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 260
Valve disease in cardiac amyloidosis: an echocardiographic score 258
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 258
Biomarkers for the diagnosis and management of heart failure: New frontiers 256
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 256
RNA-targeting and gene editing therapies for transthyretin amyloidosis 255
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 255
Disease features and management of cardiomyopathies in women 254
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 253
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 253
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 247
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 243
Biomarkers for the diagnosis and management of heart failure 241
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 238
Cardiac magnetic resonance in patients with muscular dystrophies 238
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 238
Role of Imaging in Cardiomyopathies 235
Valvular heart disease in patients with cardiac amyloidosis 235
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 234
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 231
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 231
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 230
Cardiovascular disease and COVID-19: les liaisons dangereuses 227
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 220
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 219
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 217
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 216
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 215
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 215
Molecular autopsy of sudden cardiac death in the genomics era 213
Cardiac amyloidosis: Innovations in diagnosis and treatment 212
Tissue Characterization in Cardiac Amyloidosis 211
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 210
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 208
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 206
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 205
Cardiac Amyloidosis: How Its Epidemiology is Changing 203
Cardiovascular toxicity from therapies for light chain amyloidosis 201
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 201
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 200
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 198
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 198
PET and Cardiac Amyloidosis 196
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 196
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 195
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 192
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 192
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 191
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 190
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 189
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 188
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 185
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 183
Sex differences in transthyretin cardiac amyloidosis 181
Current and emerging drug targets in heart failure treatment 178
Pathophysiology of Cardiac Amyloidosis 177
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 175
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 174
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 172
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 172
Coronary Artery Anomalies 171
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 170
Critical Reading of cardiovascular trials with neutral or negative results 168
Obstructive sleep apnea and cardiovascular diseases 166
Use of biomarkers to diagnose and manage cardiac amyloidosis 161
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 161
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 160
Treatment of cardiac transthyretin amyloidosis: an update 159
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 159
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? 158
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 158
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 155
Safety and Efficacy of Amiodarone in a Patient With COVID-19 149
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 148
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 148
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 148
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 147
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 143
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 141
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 137
Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry 131
The unbearable underreporting of comorbidities in heart failure clinical trials 131
Statin therapy in COVID-19 infection 131
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 127
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 122
Totale 24.923
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.914
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.914
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202149 0 0 0 0 0 0 0 0 0 0 0 49
2021/2022544 45 67 17 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20258.175 51 97 231 132 304 256 611 1.146 434 1.070 2.215 1.628
2025/202615.680 840 2.010 2.133 2.037 1.493 1.030 1.399 760 1.081 1.087 1.069 741
Totale 26.174